AllDocs -> cancers

1 WORLD CONGRESS ON GASTROINTESTINAL CANCER Barcelona, June16-19, 2004 The world congress on gastrointestinal cancer has its origins in the regular meetings on pharmacological treatments of colorectal cancer , partly based on Eric Van Cutsem’s (Brussels) personal interest of this disease and his effort to establish an international forum for the discussion of developments and future strategies. The world congress is now also concerned with malignancies of the liver, bile ducts, pancreas and all of the esophagus-stomach-bowel. It attracts more than 2000 people, mostly from Europe, but also from all other parts of the world. Unlike most other annual congresses, there is no famous world association or federation behind the meeting, but rather a smaller group of dedicated oncologists backed by the pharmaceutical industry with an interest in oncology. The conference has no double ...

cancer Wharton Department of Statistics Data Mining Bob Stine Department of Statistics www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Applications Marketing: Direct mail advertising (Zahavi example) Biomedical: finding predictive risk factors Financial: predicting returns and bankruptcy Role of management Setting goals Coordinating players Critical stages of modeling process Picking the model <-- My research interest Validation Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Costs False positive: treat a healthy person False negative: miss a person with the disease Example: detect osteoporosis without need for x-ray What sort of predictors, ...

cancer Wharton Department of Statistics Profiting from Data Mining Bob Stine Department of Statistics The Wharton School, Univ of Pennsylvania April 5, 2002 www-stat.wharton.upenn.edu/~bob Wharton Department of Statistics 2 Overview Critical stages of data mining process Choosing the right data, people, and problems Modeling Validation Automated modeling Feature creation and selection Exploiting expert knowledge, “insights” Applications Little detail – Biomedical: finding predictive risk factors More detail – Financial: predicting returns on the market Lots of detail – Credit: anticipating the onset of bankruptcy Wharton Department of Statistics 3 Predicting Health Risk Who is at risk for a disease? Example: detect osteoporosis ...

Changes in Body Composition During Upper Gastrointestinal Cancer Surgery A. Aslani 1 , B.A. Cooper 2 , A. Sevette 3 , R.C. Smith 3 1 Department of Nuclear Medicine, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. 2 Department of Renal Medicine, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. 3 Department of Surgery, Royal North Shore Hospital, Pacific Highway, St Leonards, NSW 2065, Australia. Abstract Background: Changes in weight and body composition (BC) are expected after most major abdominal surgery. Excess fluid retention especially may result in major morbidity in the post- operative patients. Loss of weight, itself, has been generally addressed by administration of appropriate intervention procedures. However, the components of ...

SEPTEMBER 2003 | Hem/Onc today 24 GASTROINTESTINAL CANCER DRUGS IN THE PIPELINE Information for this chart was gathered from the Pharmaceutical Research and Manufacturers of America, corporate Web sites, meeting abstracts, and the databases of H EM /O NC T ODAY . The publisher or editors do not assume responsibility for any errors or omissions. Generic Product Company Indication Phase 572016 Not yet available GlaxoSmithKline Colorectal cancer Phase 2 ABT-510 Not yet available Abbott Laboratories Colorectal cancer Phase 2 planned ABX-EGF Not yet available Abgenix Renal cancer Phase 2 Adenoviral p53 (INGN 201) Not yet available Introgen Therapeutics Esophageal squamous cell carcinoma Phase 1/2 ALVAC-CEA/B7.1 Not yet available ...

Fox Chase Cancer Center 2003 Scientific Report 1 Elin R. Sigurdson, M.D., Ph.D., Senior Member Burton L. Eisenberg,* a M.D., F.A.C.S., Senior Member John P. Hoffman, M.D., F.A.C.S., Senior Member James C. Watson, M.D., Associate Member Lydia Giles, R.N., Study Coordinator Cathy O’Hare, Senior Medical Secretary Gastrointestinal (GI) cancer surgeons provide multidisciplinary care for patients with malignant and benign tumors arising in the GI tract from the esophagus to the anus, as well as surgical evaluation and interven- tion to FCCC patients who develop non- cancer related pathology of these sites. Complete tumor resection continues to be the mainstay of optimal treatment of all localized gastrointestinal cancers, with general principles of oncologic surgery advocating removal of the primary ...

Royal College of Physicians of Edinburgh UPPER GASTROINTESTINAL CANCER Tuesday 26 October 2004 venue: The Queen Mother Conference Centre Royal College of Physicians of Edinburgh 9 Queen Street Edinburgh EH2 1JQ CPD APPROVED PGEA APPROVED Royal College of Physicians of Edinburgh Upper Gastrointestinal Cancer Tuesday 26 October 2004 Cancers of the oesophagus and stomach are highly lethal and remain a major health problem worldwide. In recent years our understanding of gastric cancer development has greatly improved but there have also been worrying developments with rapid increases in the incidence of adenocarcinomas of the oesophagus and oesophagogastric junction. Reasons for this are not clear but recent research has highlighted some of the pathophysiological and molecular events underlying cancer ...

gastrointestinal cancer 6Th FRAMEWORK PROGRAMME OF THE EUROPEAN COMMUNITY FOR RESEARCH, TECHNOLOGICAL DEVELOPMENT AND DEMONSTRATION ACTIVITIES PRIORITY 5: Food Quality and Safety 5.4.8 Area: Environmental health risks 5.4.8.1 (T44) Effects of environmental exposure to complex chemical mixtures SPECIFIC TARGETED RESEARCH PROJECT (STREP) High and low risk of gastrointestinal cancer incidence and chemical exposure related to dietary behaviour Acronym ?EUROHEALTHYFOOD? PROPOSING AGENCY Polo Oncologico ?Regina Elena?, Roma PARTNERS Istituto Zooprofilattico delle Regioni Lazio e Toscana Università degli Studi di Roma ?Tor Vergata? Regione Lazio ? Agenzia di Sanità Pubblica Regione Lazio Assessorato alla Sanità ? Servizi Veterinari Regione Toscana ...

cancer COLORECTAL CANCER William Grady, MD Division of Gastroenterology Vanderbilt University Medical Center 137,000 new cases in U.S. each year Colorectal Cancer Prevalent: 56,600 deaths, 50% five year mortality Deadly : >95% survival when detected early Treatable: Screening is effective for prevention Preventable: Colon: Anatomy and Function FUNCTION •Storage •Water absorption ANATOMY HISTOLOGY Colon Cancer : Heredity vs. Environment Sporadic Cancer ~65-90% FJP/PJS <0.1% FAP <1% HNPCC 1-2% CFCC 10-30% Adapted from Burt, Gastro, 2000 ...

up-to-date perspectives. The 4th edition takes a multidisciplinary approach to surgery and mana- gement, bringing new information on topics such as reconstruction of the vocal chords, treatment of laryngeal cancer and radiotherapy. Molecular Diagnosis of Cancer Methods and Protocols. Joseph E Roulston & John M S Bartlett Humana Press, 2 upplagan 2004. 500 sidor Best nr 158829160X Pris: 1 788,- (1 677,- exkl moms) Discusses principles of cancer diagnostics, such as prognostic, diagnostic, predictive and selective factors. Reviews common methods like DNA/RNA extraction and microdissection. Covers solid tumor diagnostics as well as leukemia and lymphoma. Addresses the use of genomic arrays in the future of molecular diagnosis of cancer . Gastrointestinal and Liver Tumors W Scheppach m fl Springer-Verlag, 2004. 600 sidor. ...

224 Anti- Cancer Treatment - 12th International Congress Third Interactive Gastrointestinal Oncology Meeting 4-7 February 2002, Paris, France Jacques Wils Address St Laurentius Ziekenhuis Mgr Driessenstraat 6 6043 CV Roermond The Netherlands Email: wils@cobweb.nl IDrugs 2002 5 (3):224-227 PharmaPress Ltd ISSN 1369-7056 Introduction The Interactive Gastrointestinal (GI) Oncology meeting was held for the third time during the 12th International Congress on Anti- Cancer Treatment on 6-7 February, 2002. The aim was to provide an authoritative and interactive GI cancer conference in a forum allowing the free exchange of scientific information. The conference was organized by Jaffer Ajani (MD Anderson Cancer Center, USA), David Kayat (Hôpital de la Pitié Salpêtrière, France), Jacques Wils (St Laurentius Ziekenhuis, ...

PRACTICAL GASTROENTEROLOGY • MARCH 2004 52 INTRODUCTION N umerous studies have been done to examine what role diet plays in protection against gastrointesti- nal cancers. In order to make the best suggestions for physicians and patients, a careful review of the data is provided. The area of diet and cancer prevention is evolving, and, at the current time, much of the data is epidemiological or from basic science animal models. Some of the data is from humans in retrospective for- mat, prospective cohorts, and a few randomized placebo controlled studies. In order to understand the evolution and how suggestions are being formed, it is essential to review all of the studies available as each type has value. This article provides a review of the best data available and makes suggestions based on the literature at hand in regards to nutrients, diet, and cancer ...

Fox Chase Cancer Center 2003 Scientific Report 1 Gastrointestinal Cancer Therapeutics. Meropol, Sigurdson, in collaboration with Allard, a Blanchard, § Cheng, § S. Cohen, § Eisenberg, § Engstrom, § Freedman, § Gallo, § Godwin, § Goldberg, § Hoffman, § Konski, § Lewis, § Rogatko, § Scott, § Szarka, § von Mehren, § Watson, § Weiner § Given the relative resistance of GI cancers to standard chemotherapeutic agents, a major emphasis of the GI cancer program at Fox Chase involves development of novel systemic approaches. Overall goals of the program are to: 1) develop treatments ...

Abstract. WNT2 gene on human chromosome 7q31 is a paralog of the WNT2B gene on human chromosome 1p13. Rat Wnt2 gene was identified within rat genome draft sequence AC095247.4. Human WNT2 showed 96.4% total-amino-acid identity with rat Wnt2, 96.1% with mouse Wnt2, 68.6% with zebrafish wnt2, and 67.8% with fugu wnt2. WNT2 is an evolutionarily conserved secreted-type glycoprotein belonging to the WNT family. WNT2 mRNA is expressed in human fetal lung and placenta, but almost undetectable in normal gastro- intestinal tract. WNT2 mRNA is frequently up-regulated in human gastric cancer due to tumor-stromal interaction, and WNT2 gene is rarely amplified in human gastric cancer . WNT2 mRNA is also frequently up-regulated in colorectal polyps, primary colorectal cancer of stage A-C, and also in liver metastasis from colorectal cancer . Putative biding sites for estrogen ...